Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML
MBRX•Interim MIRACLE trial data and next catalyst
Moleculin Biotech highlighted encouraging interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory AML.
Results have already been presented in a virtual investor “Why Now” on-demand conference.
Management framed the drug’s profile as differentiated, supporting a potential registration path if upcoming analyses remain supportive.
Focus now shifts to an upcoming interim readout at 90 patients, positioned as a key catalyst for the program.
